Evidence map›Paper›PMID 39705302›Full record

ArticlePloS one2024

Accelerating antimicrobial peptide design: Leveraging deep learning for rapid discovery.

Ahmad M Al-Omari, Yazan H Akkam, Ala'a Zyout, Shayma'a Younis, Shefa M Tawalbeh, Khaled Al-Sawalmeh, Amjed Al Fahoum, Jonathan Arnold

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ahmad M Al-OmariBiomedical Systems and Informatics Engineering Department, College of Engineering, Yarmouk University, Irbid, Jordan.
Yazan H AkkamMedicinal Chemistry and Pharmacognosy Department, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan.
Ala'a ZyoutBiomedical Systems and Informatics Engineering Department, College of Engineering, Yarmouk University, Irbid, Jordan.
Shayma'a YounisBiomedical Systems and Informatics Engineering Department, College of Engineering, Yarmouk University, Irbid, Jordan.
Shefa M TawalbehBiomedical Systems and Informatics Engineering Department, College of Engineering, Yarmouk University, Irbid, Jordan.
Khaled Al-SawalmehDepartment of Basic Pathological Sciences, College of Medicine, Yarmouk University, Irbid, Jordan.
Amjed Al FahoumBiomedical Systems and Informatics Engineering Department, College of Engineering, Yarmouk University, Irbid, Jordan.ORCID 0000-0001-5190-3048
Jonathan ArnoldGenetics Department, University of Georgia, Athens, GA, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial peptides (AMPs) are excellent at fighting many different infections. This demonstrates how important it is to make new AMPs that are even better at eliminating infections. The fundamental transformation in a variety of scientific disciplines, which led to the emergence of machine learning techniques, has presented significant opportunities for the development of antimicrobial peptides. Machine learning and deep learning are used to predict antimicrobial peptide efficacy in the study. The main purpose is to overcome traditional experimental method constraints. Gram-negative bacterium Escherichia coli is the model organism in this study. The investigation assesses 1,360 peptide sequences that exhibit anti- E. coli activity. These peptides' minimal inhibitory concentrations have been observed to be correlated with a set of 34 physicochemical characteristics. Two distinct methodologies are implemented. The initial method involves utilizing the pre-computed physicochemical attributes of peptides as the fundamental input data for a machine-learning classification approach. In the second method, these fundamental peptide features are converted into signal images, which are then transmitted to a deep learning neural network. The first and second methods have accuracy of 74% and 92.9%, respectively. The proposed methods were developed to target a single microorganism (gram negative E.coli), however, they offered a framework that could potentially be adapted for other types of antimicrobial, antiviral, and anticancer peptides with further validation. Furthermore, they have the potential to result in significant time and cost reductions, as well as the development of innovative AMP-based treatments. This research contributes to the advancement of deep learning-based AMP drug discovery methodologies by generating potent peptides for drug development and application. This discovery has significant implications for the processing of biological data and the computation of pharmacology.

Indexed as

Antimicrobial PeptidesDeep LearningEscherichia coliMicrobial Sensitivity TestsAnti-Bacterial AgentsAntimicrobial Cationic PeptidesDrug DesignDrug DiscoveryHumansMachine LearningNeural Networks, ComputerAnti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial Peptides

Identifiers

PMID39705302
PMCPMC11661626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.